We’re all about humanity
We make a difference in the lives of patients around the world with serious and rare diseases because the vitality of our science is powered by our core values.
Guided by our values
At Insmed, the needs of patients serve as our compass point when setting priorities for the company and weighing difficult decisions. Our five core values—collaboration, accountability, passion, respect, and integrity—set the tone for our culture and guide the actions we take each day.
A global commitment
Our commitment to patients has no borders. In addition to our global corporate headquarters in Bridgewater, NJ, we have offices throughout Europe and in Japan, with more than 600 employees who are dedicated to serving the needs of patients and their families. We continue to build our global infrastructure and organizational capabilities as we pursue regulatory approvals in multiple regions.
Our history
Our company has evolved significantly over the years, but our commitment to patients remains. As we look toward the future, we are inspired by our vision to deliver life-altering therapies to small patient populations experiencing big health problems.
Our key milestones
2021
Insmed’s first product is approved and launches in Japan. Insmed reports positive Phase 1 data for its earlier-stage product candidate in healthy volunteers.
2020
Insmed’s first product is approved in Europe; initial country launches begin
2020
Insmed reports positive data for its Phase 2 product candidate and announces plans to advance to Phase 3 development.
2019
Insmed opens its new, state-of-the-art global headquarters in Bridgewater, NJ, to support the Company’s continued growth.
2019
Insmed opens an office in Tokyo, expanding its global presence to Japan.
2018
Insmed is granted accelerated approval by the FDA for its first therapy.
2018
Insmed submits a New Drug Application to the FDA for its lead product candidate.
2016
Insmed opens an office in Utrecht, Netherlands, further expanding its presence to Europe.
2016
Insmed enters into a worldwide license agreement with AstraZeneca for a product candidate, expanding the company’s rare disease pipeline.
2013
Insmed receives Orphan Drug Designation, Qualified Infectious Disease Product designation, and Fast Track status for its lead product candidate.
2010
Insmed enters into a business combination with Transave, acquiring its late-stage candidate. The new company maintains the name Insmed.
2000
Transave pioneers the early development of an inhaled liposomal antibiotic, an advancement that will later enable the approval of the Company’s first therapy.
1999-2000
Insmed is incorporated in the Commonwealth of Virginia and becomes a public company (INSM) after acquiring Celtrix Pharmaceuticals in a reverse merger.
1997
Transave is founded as a private company by Dr. Frank Pilkiewicz in Monmouth Junction, NJ, to develop inhaled pharmaceuticals for the treatment of lung diseases.
1988
Insmed is founded as a private company by Dr. Joseph Larner in Charlottesville, Va., to develop medicines to treat diabetes.
History wall
An installation at Insmed’s global headquarters honors the Company’s past as we look toward the future. From the early days of the two original companies that formed Insmed to the FDA approval and launch of our first therapy, the wall highlights some of the most significant moments in Insmed’s history and showcases the values that we live every day.
